TY - JOUR
T1 - Assessing Tumor-infiltrating Lymphocytes in Solid Tumors
T2 - A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
AU - Hendry, Shona
AU - Salgado, Roberto
AU - Gevaert, Thomas
AU - Russell, Prudence A
AU - John, Tom
AU - Thapa, Bibhusal
AU - Christie, Michael
AU - van de Vijver, Koen
AU - Estrada, M V
AU - Gonzalez-Ericsson, Paula I
AU - Sanders, Melinda
AU - Solomon, Benjamin
AU - Solinas, Cinzia
AU - Van den Eynden, Gert G G M
AU - Allory, Yves
AU - Preusser, Matthias
AU - Hainfellner, Johannes
AU - Pruneri, Giancarlo
AU - Vingiani, Andrea
AU - Demaria, Sandra
AU - Symmans, Fraser
AU - Nuciforo, Paolo
AU - Comerma, Laura
AU - Thompson, E A
AU - Lakhani, Sunil
AU - Kim, Seong-Rim
AU - Schnitt, Stuart
AU - Colpaert, Cecile
AU - Sotiriou, Christos
AU - Scherer, Stefan J
AU - Ignatiadis, Michail
AU - Badve, Sunil
AU - Pierce, Robert H
AU - Viale, Giuseppe
AU - Sirtaine, Nicolas
AU - Penault-Llorca, Frederique
AU - Sugie, Tomohagu
AU - Fineberg, Susan
AU - Paik, Soonmyung
AU - Srinivasan, Ashok
AU - Richardson, Andrea
AU - Wang, Yihong
AU - Chmielik, Ewa
AU - Brock, Jane
AU - Johnson, Douglas B
AU - Balko, Justin
AU - Wienert, Stephan
AU - Criscitiello, Carmen
AU - Curigliano, Giuseppe
AU - Dieci, Maria V
PY - 2017/9
Y1 - 2017/9
N2 - Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
AB - Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
U2 - 10.1097/PAP.0000000000000162
DO - 10.1097/PAP.0000000000000162
M3 - Article
C2 - 28777142
VL - 24
SP - 235
EP - 251
JO - Advances in Anatomic Pathology
JF - Advances in Anatomic Pathology
SN - 1072-4109
IS - 5
ER -